Wells Fargo Maintains Overweight on Boston Scientific, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Negative 86.8%

Neg 86.8% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Overweight and lowers the price target from $94 to $75.